Antiviral resistance in influenza viruses--implications for management and pandemic response.
Hayden
Frederick G
FG
Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, USA.
D000547:Amantadine / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000517:prevention & control; D024882:Drug Resistance, Viral; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology; D009154:Mutation; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012299:Rimantadine / Q000494:pharmacology / Q000627:therapeutic use; D014763:Viral Matrix Proteins / Q000037:antagonists & inhibitors*; D014779:Virus Replication / Q000187:drug effects; D000086082:Viroporin Proteins
D000547:Amantadine; D000998:Antiviral Agents; D009439:Neuraminidase; D019384:Nucleic Acid Synthesis Inhibitors; D012299:Rimantadine; D014763:Viral Matrix Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins